This is a Phase 1 study (the first time this treatment is being tested in humans) of an anti-cancer study drug called as PF-07225570. This study drug works on stimulating certain cells in the immune system. The study will test different doses that increase (dose escalation) and at the appropriate…
The purpose of this study is testing two different Janus kinase (JAK) inhibitors, Abrocitinib and Ritlecitinib, to see if either or both can preserve insulin production in people recently diagnosed with type 1 diabetes (T1D). Researchers believe JAK inhibitors may be able to calm the immune system's attack on insulin producing…